Why Australia’s conditional approval of Amtagvi matters for Iovance investors

Australia’s Therapeutic Goods Administration has granted conditional approval for Amtagvi, giving Iovance Biotherapeutics (IOVA) a third marketing authorization for its T cell therapy and reinforcing the product’s expanding international footprint in melanoma treatment.

The Australian green light for Amtagvi comes as Iovance’s share price shows strong recent momentum, with a 30 day share price return of 18.26% and a year to date share price return of 61.90%, while the 1 year total shareholder return of 82.14% contrasts with weaker 3 and 5 year total shareholder returns.

If this kind of oncology progress has your attention, it could be a good moment to see what other healthcare focused AI opportunities are setting up via 40 healthcare AI stocks

With Iovance shares up sharply over the past year and trading at a steep discount to the average analyst price target, the key question now is simple: is there still upside potential here, or has the market already priced in future growth?

Most Popular Narrative: 51.1% Undervalued

At a last close of $4.08 versus a narrative fair value of $8.35, the current pricing sits well below what the most followed model suggests, putting extra focus on the assumptions behind that gap.

Advancing multiple late-stage clinical programs for TIL therapies across solid tumor types (lung, endometrial, next-gen approaches) not only opens new addressable markets but also reduces reliance on Amtagvi alone, diversifying future revenue streams and stabilizing earnings outlook.

Want to see what this expansion story is built on? Revenue curves, margin shifts and a punchy profit multiple all sit at the core of this fair value call.

Result: Fair Value of $8.35 (UNDERVALUED)

However, the story can change quickly if regulatory setbacks continue or if dependence on Amtagvi leaves Iovance exposed to weaker demand or pricing pressure.

Next Steps

Does this mix of optimism and concern around Iovance match your own read of the situation, or does it feel different when you see the numbers side by side? Take a moment to review both sides of the debate with the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you only focus on a single stock, you risk missing other opportunities setting up right now, so broaden your watchlist with a few targeted screens.

• Spot potential turnaround stories by scanning 24 elite penny stocks with strong financials that already show stronger financials than many expect from lower priced stocks.
• Target quality at a discount by reviewing 44 high quality undervalued stocks that pair solid business fundamentals with prices that sit below their underlying metrics.
• Prioritise resilience by using the 71 resilient stocks with low risk scores to focus on companies with characteristics that may help cushion portfolios in tougher periods.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.